DGIdb - CAPMATINIB Drug Record

CAPMATINIB chembl:CHEMBL3188267 Antineoplastic

Alternate Names:

INCB-28060 FREE BASE
INCB-28060
NYP-INC280-NX
INC-280
NVP-INC280
CAPMATINIB
NVP-INC280-NX
INC280
TABRECTA
INCB28060
chemidplus:1029712-80-8
pubchem.compound:25145656
drugbank:11791
chembl:CHEMBL3188267

Drug Info:

Drug Class	Kinase Inhibitors
Pharmaceutical Developer	Novartis
Source Reported Drug Name(s)	INC280
Drug Class	MET Inhibitor
Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational
Drug Categories	acids, carbocyclic
Drug Categories	amides
Drug Categories	antineoplastic agents
Drug Categories	bcrp/abcg2 inhibitors
Drug Categories	benzene derivatives
Drug Categories	benzoates
Drug Categories	cytochrome p-450 cyp1a2 inhibitors
Drug Categories	cytochrome p-450 cyp1a2 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 substrates
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	mate 1 inhibitors
Drug Categories	mate 2 inhibitors
Drug Categories	mate inhibitors
Drug Categories	p-glycoprotein substrates
Drug Categories	tyrosine kinase inhibitors

(8 More Sources)

Publications:

Yao et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature
Frampton et al., 2015, Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors., Cancer Discov
Li et al., 2017, Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer., Clin. Cancer Res.
Choi et al., 2004, Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein., Cancer Cell Int.
Bahcall et al., 2016, Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer., Cancer Discov
Engstrom et al., 2017, Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models., Clin. Cancer Res.
Wolf J et al., 2020, Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung Cancer., N Engl J Med

CAPMATINIB MET

Interaction Score: 2.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Indication/Tumor Type lung large cell carcinoma

Response Type sensitive

PMIDs:
28396313 15494073 28783719 27694386 28765324 25971938 32877583

Sources:
TALC DrugBank MyCancerGenome JAX-CKB ChemblInteractions COSMIC CIViC GuideToPharmacology CancerCommons TTD OncoKB
CAPMATINIB BRAF

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type collecting duct carcinoma

Response Type sensitive

Approval Status Preclinical - Pdx

PMIDs:
28783719

Sources:
JAX-CKB
CAPMATINIB EGFR

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type collecting duct carcinoma

Approval Status Preclinical - Pdx

combination therapy INC280 + Trametinib

PMIDs:
28783719

Sources:
JAX-CKB
CAPMATINIB TP53

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Clinical Study

Response Type sensitive

PMIDs:
25971938

Sources:
JAX-CKB

MyCancerGenome: INCB028060
- Version: 20-Jun-2017
Alternate Names:

INCB028060 Development Name

INC280 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
CancerCommons: INC280
- Version: 25-July-2013
Alternate Names:

INC280 Drug Trade Name

INC280 Drug Development Name

Drug Info:

Drug Class MET Inhibitor

Source Reported Drug Name(s) INC280

Pharmaceutical Developer Novartis

Publications:
DrugBank: DB11791
- Version: 5.1.7
Alternate Names:

CAPMATINIB DrugBank Drug Name

1029712-80-8 CAS Number

Tabrecta Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

JAX-CKB: INC280

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Yao et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature

Frampton et al., 2015, Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors., Cancer Discov

Engstrom et al., 2017, Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models., Clin. Cancer Res.

CIViC: CAPMATINIB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Wolf J et al., 2020, Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung Cancer., N Engl J Med

Frampton et al., 2015, Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors., Cancer Discov

TTD: INCB28060
- Version: 2020.06.01
Alternate Names:

D07OJZ TTD Drug ID

Drug Info:

Publications:
TALC: INCB28060
- Version: 12-May-2016
Alternate Names:

INCB28060 Primary Drug Name

INCB28060 Drug Synonym

Drug Info:

Publications:
GuideToPharmacology: 249565587
- Version: 29-September-2020
Alternate Names:

CAPMATINIB GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL3188267
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL3188267
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
OncoKB: Capmatinib
- Version: 23-July-2020
Alternate Names:

Drug Info:

Publications:
COSMIC: Capmatinib
- Version: 4-Sep-2020
Alternate Names:

Drug Info:

Publications:

Reported Cancer Type	Melanoma
Indication/Tumor Type	lung large cell carcinoma
Response Type	sensitive

Indication/Tumor Type	collecting duct carcinoma
Response Type	sensitive
Approval Status	Preclinical - Pdx

Evidence Type	Actionable
Approval Status	Clinical Study
Response Type	sensitive

CAPMATINIB	DrugBank Drug Name
1029712-80-8	CAS Number
Tabrecta	Drug Brand

INCB028060	Development Name
INC280	Development Name

CAPMATINIB Drug Record

CAPMATINIB chembl:CHEMBL3188267 Antineoplastic

Alternate Names:

Drug Info:

Publications:

CAPMATINIB MET

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Reported Cancer Type Melanoma Indication/Tumor Type lung large cell carcinoma Response Type sensitive

PMIDs: 28396313 15494073 28783719 27694386 28765324 25971938 32877583

Sources: TALC DrugBank MyCancerGenome JAX-CKB ChemblInteractions COSMIC CIViC GuideToPharmacology CancerCommons TTD OncoKB

CAPMATINIB BRAF

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type collecting duct carcinoma Response Type sensitive Approval Status Preclinical - Pdx

PMIDs: 28783719

Sources: JAX-CKB

CAPMATINIB EGFR

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type collecting duct carcinoma Approval Status Preclinical - Pdx combination therapy INC280 + Trametinib

PMIDs: 28783719

Sources: JAX-CKB

CAPMATINIB TP53

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Clinical Study Response Type sensitive

PMIDs: 25971938

Sources: JAX-CKB

MyCancerGenome: INCB028060

Alternate Names: INCB028060 Development Name INC280 Development Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

CancerCommons: INC280

Alternate Names: INC280 Drug Trade Name INC280 Drug Development Name

Drug Info: Drug Class MET Inhibitor Source Reported Drug Name(s) INC280 Pharmaceutical Developer Novartis

Publications:

DrugBank: DB11791

Alternate Names: CAPMATINIB DrugBank Drug Name 1029712-80-8 CAS Number Tabrecta Drug Brand

Drug Info: Drug Type small molecule Drug Groups approved Drug Groups investigational

Publications:

JAX-CKB: INC280

Alternate Names:

Drug Info:

CIViC: CAPMATINIB

Alternate Names:

Drug Info:

TTD: INCB28060

Alternate Names: D07OJZ TTD Drug ID

Drug Info:

Publications:

TALC: INCB28060

Alternate Names: INCB28060 Primary Drug Name INCB28060 Drug Synonym

Drug Info:

Publications:

GuideToPharmacology: 249565587

Alternate Names: CAPMATINIB GuideToPharmacology Ligand Name

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL3188267

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL3188267

Alternate Names:

Drug Info:

Publications:

OncoKB: Capmatinib

Alternate Names:

Drug Info:

Publications:

COSMIC: Capmatinib

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Indication/Tumor Type lung large cell carcinoma

Response Type sensitive

PMIDs:
28396313 15494073 28783719 27694386 28765324 25971938 32877583

Sources:
TALC DrugBank MyCancerGenome JAX-CKB ChemblInteractions COSMIC CIViC GuideToPharmacology CancerCommons TTD OncoKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type collecting duct carcinoma

Response Type sensitive

Approval Status Preclinical - Pdx

PMIDs:
28783719

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type collecting duct carcinoma

Approval Status Preclinical - Pdx

combination therapy INC280 + Trametinib

PMIDs:
28783719

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Clinical Study

Response Type sensitive

PMIDs:
25971938

Sources:
JAX-CKB

Alternate Names:

INCB028060 Development Name

INC280 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Alternate Names:

INC280 Drug Trade Name

INC280 Drug Development Name

Drug Info:

Drug Class MET Inhibitor

Source Reported Drug Name(s) INC280

Pharmaceutical Developer Novartis

Alternate Names:

CAPMATINIB DrugBank Drug Name

1029712-80-8 CAS Number

Tabrecta Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Alternate Names:

D07OJZ TTD Drug ID

Alternate Names:

INCB28060 Primary Drug Name

INCB28060 Drug Synonym

Alternate Names:

CAPMATINIB GuideToPharmacology Ligand Name